Schedule at a Glance

Monday, October 16, 2023
1:00 PM to 5:00 PM
Featured Topic
  • 1) Introducing the Featured Topic
  • 2) Clinician’s Perspective on Car T Cells and Allogeneic Immune Effector Cells
  • 3) NK Cells vs. T cells: What is Ideal Cell for Allogeneic Immune Effector Cellular Therapy?
  • 4) Transient and Stable Chimerism-Mediated Clinical Transplant Tolerance
  • 5) Regulatory T Cell Therapy in Human (Autoimmunity and) Transplantation
  • 6) Engineered Cells and CAR-Tregs as Potential Tools for Tolerance Induction
  • 7) The Role of FACT Accreditation in Cellular Therapy
1:00 PM to 4:00 PM
5:00 PM to 6:00 PM
6:00 PM to 7:00 PM
7:00 PM to 9:00 PM
Tuesday, October 17, 2023
6:45 AM to 8:00 AM
8:00 AM to 8:30 AM
8:30 AM to 9:30 AM
9:30 AM to 10:00 AM
10:00 AM to 10:30 AM
Scholar Presentations
  • Crosstalk between HLA Class I and TLR4 Mediates Pro-Inflammation Signaling Cascades in Endothelial Cells via TLR4/MyD88 Pathway
  • Substitution of Glutamic Acid at Position 71 of DRB1*04:01 Eliminates Collagen Sensitivity without Inducing Alloreactivity
10:30 AM to 12:00 PM
Plenary I
  • 1) Multi-omic Profiling of Immunity to Infectious Disease
  • 2) Single cell/CTYOF Immunophenotyping in Transplant Rejection
  • 3) Radiomics to Pathomics: Converting Images into Precision Medicine
12:15 PM to 2:05 PM
2:15 PM to 3:45 PM
Abstract Session I
  • 1) Presumed or Functional Epitope: The Need for Confirmation with Cell-Based Assays
  • 2) Estimating Rates of Immunologically Incompatible Organ Offers Caused by Use of Antigen-Level Deceased Donor HLA Typing for Allocation
  • 3) Toward a Combined DR+DQ HLA Molecular Mismatch Score for Risk Stratification of Pediatric Heart Transplant Patients
  • 4) Impact of Induction on Acute Rejection in Kidney Transplant Recipients with High and Low Risk Class II Eplet Mismatches
  • 5) HLA Common Null Allele Detection Using a Fast and Easy CRISPR-Cas Assay
  • 6) Combining Allele-Specific Solvent - Accessible Surface-Protruding Amino Acid Mismatches and Predicted Indirect T Cell Epitopes Improves HLA Matching in Predicting Kidney Graft Survival
Abstract Session II
  • 2) Effector Memory and Th17 CD4+ T Cells are Increased in Liver Transplant Patients Experiencing Ischemia-Reperfusion Injury
  • 2) Effector Memory and Th17 CD4+ T Cells are Increased in Liver Transplant Patients Experiencing Ischemia-Reperfusion Injury
  • 3) Detection of Circulating HLA-E in Cancer Patients: Potential Applications in Cancer Immunotherapy
  • 4) A Comparison of Human Leukocyte Antigen Antibody Profiles between Circulating and Reactivated Memory B Cells
  • 5) Interrogating DSA IgG Characteristics and Effector Functions in Lung Transplant Recipients
  • 6) Donor Endothelial Activation by Serum from Mismatched Recipients
Workshop 1
  • 1) The Tip of the Spear: Innate Cells as the First Responders in Immunity
  • 2) Adaptive Immunity Defining Specificity and Pathogenicity
3:45 PM to 4:15 PM
4:15 PM to 5:45 PM
Abstract Session III
  • 1) HLA-L Pseodogene as a Potential MicroRNA Sponge for Regulation of HLA-B
  • 2) The Transcriptional Repressor BCL6 Selectively Restrains Expression of HLA Class II and Antigen Presentation Machinery in Endothelial Cells
  • 3) HLA-DQ Promiscuity across Loci?
  • 4) Characterization of HLA Expression on Memory-Like (ML) NK Cells
  • 5) Extensive Organ-Specific Heterogeneity of HLA Expression in Endothelial Cells
  • 6) Differential Pairing of Transmembrane Domain GxxxG Dimerization Motifs Generates Two HLA-DR Conformers Defined by Selective Binding by the mAb Tü36
Workshop 2
  • 1) DSA Monitoring: One Size Does Not Fit All
  • 2) The Clinical Impact of DSA in Transplant Recipients Pre- and Post-Transplant
  • 3) Biopsy and Non-Invasive Monitoring for Allograft Rejection
Workshop 3
  • 1) Introduction to Bioinformatics Concepts for Clinical Lab Management
  • 2) Understanding and Applying PIRCHE Epitope Matching in Clinical Transplantation
  • 3) Imputation: Friend or Foe?
6:00 PM to 7:00 PM
6:00 PM to 8:00 PM
6:30 PM to 7:30 PM
7:00 PM to 8:00 PM
Wednesday, October 18, 2023
6:30 AM to 8:00 AM
8:30 AM to 9:30 AM
9:30 AM to 10:00 AM
10:00 AM to 10:30 AM
10:30 AM to 12:00 PM
Plenary II
  • 1) How Matched is a MUD? MHC Comparisons in Unrelated HCT
  • 2) Human Pangenomic Graph Analysis for the MHC
  • 3) MHC Genomic Diversity and HCT Donor Selection
12:15 PM to 2:05 PM
2:15 PM to 3:45 PM
Abstract Session IV
  • 1) A Computational HLA Allele-Typing Protocol to De-Noise and Leverage Nanopore Amplicon Data
  • 2) HLA Genotype Imputation Results in Largely Accurate Epitope Mismatch Risk Categorization across Racial Groups
  • 3) Identification of DRB1 and DQB1 Amino Acid Variability within Serologic Antigen Groups
  • 4) The Accuracy of Eplet Mismatching Using Imputed Intermediate Resolution HLA Typing
  • 5) Global Coverage for iPSC Banks: Balancing Equity and Volume
  • 6) Bioinformatic Segregation of Chimeric Libraries Enables Accurate Donor HLA Typing from Allograft Biopsies by ONT
Workshop 4
  • 1) Intro to ML Applications in Transplantation and More
  • 2) Machine Learning Methods for Evaluating Graft Failure Risk in Kidney Transplantation
  • 3) HCT Survival Models for Multiple Match Scenarios
Workshop 5
  • 1) HLA Antibody Analysis in Transplantation: Standardization, Methods, Comparative Approaches and The Future…
  • 2) Keeping Up With the Times: Implementing Changes to Outdated Antibody Testing Workflows to Improve Risk Assessment for Transplant Candidates and Recipients
  • 3) Many Roads Leading to the Same Place: Different Approaches to HLA Antibody Testing for Safe and Efficient Transplantation
Workshop 6
  • 1) HCT Unrelated Donor Selection: Current NMDP/CIBMTR Guidelines & Emerging trends)
  • 2) Traveler’s Guide to NMDP Resources and Tools
  • 3) Real-World Use Cases: HCT Donor Selection in Different Clinical Scenarios
3:45 PM to 4:15 PM
4:15 PM to 5:15 PM
4:15 PM to 5:45 PM
5:15 PM to 6:15 PM
STAR Report
  • 1) The Role of Non-HLA Antibody Testing in Solid Organ Transplantation
  • 2) Measuring Levels of HLA Antibodies to Assess Efficacy of Antibody Removal Therapy
  • 3) Review of Primary and Memory Alloimmune Responses and HLA Antibody Attributes
Thursday, October 19, 2023
6:45 AM to 7:45 AM
8:00 AM to 8:45 AM
8:45 AM to 9:30 AM
9:30 AM to 10:00 AM
10:00 AM to 10:30 AM
Scholar Presentation
  • Endothelial Cells Exhibit an Imbalance in Classical, Non-Classical and Accessory HLA Molecule Expression
  • Site-Directed Mutagenesis of HLA-DQ Molecules Reveals the Amino Acids Crucial for Binding to Human Monoclonal HLA-Specific Antibody
10:30 AM to 12:00 PM
Plenary III
  • 1) Innate Allorecognition and Formation of Memory in the Myeloid Compartment
  • 2) NK Cell Mechanisms of Injury in Lung Transplantation
  • 3) Endothelial Injury: Crosstalk with Inflammatory Signaling
12:15 PM to 2:05 PM
2:15 PM to 3:45 PM
Abstract V
  • 1) The Performance of a Research Hybrid-Capture NGS Assay for High-Resolution HLA Typing
  • 2) NGS HLA Typing Reveals Low-Level Maternal T Cell Engraftment through the Detection of an Unexpected DRB4
  • 3) Use of Multiplexed, Digital PCR to Assess Cellular Chimerism and HLA Loss of Heterozygosity Following Allogeneic Stem Cell Transplantation
  • 4) A Novel Multiplex Digital PCR Technology for Accurate and Rapid Chimerism Testing
  • 5)Technology Advancement in Getting Donor HLA Information from Recipient with Unknown Donor Typing
  • 6) HLA-Typing Using a Long-Read HLA Capture Method Combined with ONT or PacBio Sequencing
Practical Applications
  • 1) Hemagglutination Assay Limits Access to ABO-A2 Kidney Transplantation
  • 2) Heart after Liver Transplant with Domino Liver (HALT-D) for a High CPRA Patient
  • 3) B cell FCXM, We've Been Doing It Wrong All Along
  • 4) Validation of Wipe Testing Using the Alloseq HCT Platform
  • 5) A Web-Based Visualization Tool for Asymmetric Linkage Disequilibrium (ALD) between Amino Acid Positions of Classical HLA in Loci in US Populations
  • 6) Common, Intermediate, Well-Documented and Rare HLA Eplets in the World Population: epCIWDR Version 1.0.0
Workshop 7
  • 1) Introduction
  • 2) Best Practice in Antibody Testing, a Medium Sized Lab Approach
  • 3) Best Practice in Antibody Testing, a Large Sized Lab Approach
  • 4) Best Practice in Antibody Testing, an International Lab Approach
4:00 PM to 5:30 PM
Plenary IV
  • 1) New Approaches to Desensitization: What We Have Learned and Where is it Leading Us?
  • 2) Heterogeneity of Pathogenic HLA-specific Human Bone Marrow Plasma Cells Have Implications in Transplant Desensitization Therapies
  • 3) Fusion Protein Engineering for Antigen-specific Humoral Tolerance
5:30 PM to 6:00 PM
9:00 PM to 11:00 PM
Friday, October 20, 2023
8:00 AM to 9:00 AM
9:00 AM to 9:15 AM
9:15 AM to 9:30 AM
9:30 AM to 10:30 AM
Plenary V
  • 1) ABO Genotyping: The New Frontier
  • 2) Donor Selection for Allogeneic Hematopoietic Cell Transplantation and the Role of ABO
10:30 AM to 12:00 PM